Our next-generation, FDA-approved liquid biopsy comprehensive genomic profiling service, a minimally-invasive option, alternative or complementary to FoundationOne CDx, for all patients with solid tumours at optimal times beneficial to their treatment journey.1–3
*Base substitutions, insertions or deletions, copy number alterations and gene rearrangements.
†309 genes with complete coding exonic coverage, 15 genes with select intronic or non-coding regions only.
‡FoundationOne Liquid CDx reports MSI-H status.
§Validation based on overall >7500 samples covering >30,000 unique variants across >300* genes and 37 cancer indications. Clinical validation demonstrated concordance with the following diagnostics: cobas® EGFR Mutation Test v2, a tumour tissue polymerase chain reaction-based clinical trial assay (CTA), and an externally validated circulating cell-free DNA-based next-generation sequencing assay. To learn more about the clinical and analytical validation of FoundationOne Liquid CDx, click here.
¥75 genes are baited with enhanced sensitivity for all variant types (selected based on increased actionability with current or future targeted therapies; for more information of these 75 genes, please refer to our full gene list); other genomic regions are baited with high sensitivity.
¶Clinical validation based on evidence gathered using an earlier version of Foundation Medicine’s current liquid biopsy service, FoundationOne Liquid CDx. For concordance results between these two tests, please see our full intended use at https://www.foundationmedicine.qarad.eifu.online/foundationmedicine/en/foundationmedicine.
‖Therapies contained in the EU version of the report may have been approved through a centralised EU procedure or a national procedure in an EU Member State.
**For additional information on the NCCN categories please refer to the NCCN Compendium® (www.nccn.org).
bTMB, blood Tumour Mutational Burden; cfDNA, circulating cell-free DNA; d, days; FDA: US Food and Drug Administration; MSI, Microsatellite Instability; NCCN, National Cancer Center Network; NSCLC, non-small cell lung cancer.
Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine®, Inc. Roche is the licensed distributor of Foundation Medicine® products outside of the United States.